UniQure Shares Drop 67% After FDA Questions Huntington’s Disease Therapy
UniQure's plans to submit its Huntington's disease gene therapy, AMT-130, for FDA approval are now uncertain after the agency indicated it no longer considers existing data sufficient, marking a significant shift from previous communications and causing a 60% drop in the company's premarket shares.